CMMB Q4 2023 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$16,173

Operating Income

-$4M

Net Income

-$3M

EPS (Diluted)

$-1.06

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$22M

Total Liabilities

$5M

Stockholders' Equity

$17M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$16,173	-$13,962	-15.8%
Operating Income	-$4M	-$9M	+55.5%
Net Income	-$3M	-$8M	+58.2%